359877-98-8

Usage

Chemical class

Piperidine derivative

Functional groups

BOC (tert-butoxycarbonyl) protecting group
Bromo-benzylamino group

Structure

A piperidine ring with a BOC group at the 1-position
A benzylamino group at the 4-position, with a bromine atom at the 3-position of the benzene ring

Applications

Organic synthesis
Medicinal chemistry (building block for biologically active molecules)
Precursor for functionalized piperidine derivatives

Reactivity

The BOC group protects the amine from unwanted reactions
The bromo-benzylamino group allows for further chemical reactions

Utility

Versatile compound with potential in organic synthesis and medicinal chemistry
These properties and contents provide a comprehensive overview of 1-BOC-4-(3-BROMO-BENZYLAMINO)-PIPERIDINE, highlighting its structure, functional groups, and potential applications in various fields.

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 1044183-50-7 4-(benzylidene-amino)-piperidine-1-carboxylic acid tert-butyl ester 
• 1029643-92-2 N-phenylmethylidenepiperidinyl-4-amine 
• 13035-19-3 4-aminopiperidine 
• 41979-39-9 4-piperidone hydrochloride 
• 10269-01-9 3-bromobenzylamine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 846605-63-8 4-[(3-bromo-benzyl)-(4-pentyl-benzoyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 1401462-31-4 (S)-tert-butyl 4-(3-(7-(3-(2-methylpyrrolidin-1-yl)phenylamino)thiazolo[5,4-d]pyrimidin-5-yl)benzylamino)piperidine-1-carboxylate 
• 1401532-94-2 C₂₁H₂₀BrClN₂OS 
• 1401533-12-7 C₂₆H₂₈BrClN₂O₃S 

Relevant academic research and scientific papers

Design and synthesis of selective, small molecule inhibitors of coactivator-associated arginine methyltransferase 1 (CARM1)

Coactivator-associated arginine methyltransferase 1 (CARM1) is a type I protein arginine methyltransferase (PRMT) that catalyzes the conversion of arginine into monomethylarginine (MMA) and further into asymmetric dimethylarginine (ADMA). CARM1 methylates histone 3 arginines 17 and 26, as well as numerous non-histone proteins including CBP/p300, SRC-3, NCOA2, PABP1, and SAP49, while also functioning as a coactivator for various proteins that have been linked to cancer such as p53, NF-κβ, β-catenin, E2F1 and steroid hormone receptor ERα. As a result, CARM1 is involved in transcriptional activation, cellular differentiation, cell cycle progression, RNA splicing and DNA damage response. It has been associated with several human cancers including breast, colon, prostate and lung cancers and thus, is a potential oncological target. Herein, we present the design and synthesis of a series of CARM1 inhibitors. Based on a fragment hit, we discovered compound 9 as a potent inhibitor that displayed selectivity for CARM1 over other PRMTs.

AZACYCLIC COMPOUNDS

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Potent small molecule Hedgehog agonists induce VEGF expression in vitro

Here, we describe the synthesis, SAR studies as well as biological investigations of the known Hedgehog signaling agonist SAG and a small library of its analogues. The SAG and its derivatives were analyzed for their potency to activate the expression of the Hh target gene Gli1 in a reporter gene assay. By analyzing SAR important molecular descriptors for Gli1 activation have been identified. SAG as well as compound 10c proven to be potent activators of VEGF expression in cultivated dermal fibroblasts. Importantly and in contrast to SAG, derivative 10c displayed no toxicity in concentrations up to 250 μm.

THIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to the use of novel pyrrolopyrazine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

THIAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to the use of novel pyrrolopyrazine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.

SUBSTITUTED AMINO-AZA-CYCLOHEXANES

The invention relates to novel amino-aza-cyclohexane derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of plasmepsin II.

Azacyclic compounds

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.